Arcutis Biotherapeutics (ARQT) Operating Margin (2022 - 2025)
Historic Operating Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to 8.59%.
- Arcutis Biotherapeutics' Operating Margin rose 958800.0% to 8.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.03%, marking a year-over-year increase of 1191300.0%. This contributed to the annual value of 65.33% for FY2024, which is 3391600.0% up from last year.
- Latest data reveals that Arcutis Biotherapeutics reported Operating Margin of 8.59% as of Q3 2025, which was up 958800.0% from 17.93% recorded in Q2 2025.
- In the past 5 years, Arcutis Biotherapeutics' Operating Margin registered a high of 8.59% during Q3 2025, and its lowest value of 14448.0% during Q3 2022.
- Over the past 4 years, Arcutis Biotherapeutics' median Operating Margin value was 123.01% (recorded in 2023), while the average stood at 1671.81%.
- Per our database at Business Quant, Arcutis Biotherapeutics' Operating Margin skyrocketed by 143249900bps in 2023 and then surged by 265400bps in 2025.
- Quarter analysis of 4 years shows Arcutis Biotherapeutics' Operating Margin stood at 2310.84% in 2022, then skyrocketed by 80bps to 452.23% in 2023, then surged by 98bps to 10.7% in 2024, then soared by 180bps to 8.59% in 2025.
- Its Operating Margin was 8.59% in Q3 2025, compared to 17.93% in Q2 2025 and 37.25% in Q1 2025.